Infectious Diseases News and Research

RSS

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.

17 Apr 2013

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Vygon, a French family-run business that develops, produces and markets medical devices, including catheters and implantable ports for administering chemotherapy treatments, today announce their partnership to develop a new generation of innovative medical devices; mainly for use in chemotherapy. The partnership aims to introduce them to European, the US and Asian markets.

16 Apr 2013

Pakistani Taliban deny responsibility for attacks on polio workers

"The Pakistani Taliban on Friday denied any involvement in attacks on polio workers, which have killed 21 people since December, but confirmed it opposed the vaccination as 'un-Islamic,'" Agence France-Presse reports.

16 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Malaria control strategies must adapt to rapidly changing patterns of infection

Malaria control strategies must keep up with the rapidly changing patterns of malaria infection in low transmission settings, according to the authors of a new Review, published in The Lancet. Whereas women and young children suffer from the greatest burden of malaria in high transmission areas, an increasing proportion of malaria cases in low transmission settings are occurring in adult men, sometimes concentrated in small geographic areas and sharing certain occupations or behaviours.

15 Apr 2013

Blog features guest posts discussing Rally for Medical Research

The Global Health Technologies Coalition's "Breakthroughs" blog this week featured three guest posts addressing this week's Rally for Medical Research in Washington, D.C.

15 Apr 2013

New data on T cells' protective role suggests need for new approach to dengue vaccine design

As efforts to create a strong and effective vaccine for the dreaded dengue virus continue to hit snags, a new study from researchers at the La Jolla Institute for Allergy & Immunology offers surprising evidence that suggests the need for a revamped approach to dengue vaccine design.

15 Apr 2013

Genetic analysis of H7N9 portrays that virus evolves to adapt to human cells

A genetic analysis of the avian flu virus responsible for at least nine human deaths in China portrays a virus evolving to adapt to human cells, raising concern about its potential to spark a new global flu pandemic.

15 Apr 2013

US biochemist to be honoured with Inhoffen Medal Braunschweig, Germany

How do bacteria cope when exposed to toxic mercury, how are they able to outlast antibiotics, and how can they be killed using so-called "suicide inhibitors?" These are but a few of the many research topics US biochemist Christopher Walsh has devoted his career as a scientist to.

15 Apr 2013

New approaches to treat persistent viral infections like HIV and hepatitis C

UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.

12 Apr 2013

Australian, Singapore researchers join hands to combat disease-causing bugs

The fight against a number of significant infectious diseases in the Asia-Pacific region has been given a boost through a new research collaboration between the National Health and Medical Research Council in Australia and the Agency for Science, Technology and Research in Singapore.

12 Apr 2013

Experts launch new strategy to eradicate polio by 2018

Hundreds of scientists, doctors and other experts from around the world launched the Scientific Declaration on Polio Eradication today, declaring that an end to the paralyzing disease is achievable and endorsing a comprehensive new strategy to secure a lasting polio-free world by 2018.

12 Apr 2013

Researchers identify defective gene responsible for isolated congenital asplenia

The spleen is rarely noticed, until it is missing. In children born without this organ, that doesn't happen until they become sick with life-threatening bacterial infections.

12 Apr 2013

New tool to identify air travelers with infectious disease developed

Researchers have developed a simple new tool to help governments worldwide decide whether to screen airplane passengers leaving or arriving from areas of infectious disease outbreaks.

11 Apr 2013

Gold nano-bullets to defeat cancer

Cutting edge research into an experimental therapy that deploys nano-particles of gold in the fight against cancer earned an Alberta high school student, 16, top national honours today in the 2013 "Sanofi BioGENEius Challenge Canada" (SBCC).

11 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Research opens new avenue for treatment of melanoma

For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin cancer.

11 Apr 2013

Scientists demonstrate feasibility of using already-approved drugs against pathogens

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses.

11 Apr 2013